Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Keywords: CAR T cells; cancer treatment; genetic modification of T cells; immunotherapy.
Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.